AcquisitionApr 27, 2026Completed
🇺🇸 United States
XRXOMA Royalty CorporationLPLigand Pharmaceuticals Incorporated
Financial Institutions › Specialty Finance & Fintech
Equity value$739MEquity value
AnnouncedApr 27, 2026
ConsiderationCash
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
Ligand Pharmaceuticals agreed to acquire XOMA Royalty for $39.00 per share in cash, about $739 million in total equity value, plus one non-transferable CVR per share tied to net proceeds from litigation against Janssen Biotech.
Deal rationale
The acquisition expands Ligand's royalty portfolio to more than 200 assets, adds seven commercial products, diversifies its growth, and is expected to be immediately accretive to adjusted EPS.
AI-generated from the SEC filingCompletedFinancial Institutions › Specialty Finance & FintechUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $739M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Cash |
Advisors
Buy-side
CCitiSStifel
Sell-side
HCH.C. Wainwright & Co.LPLeerink Partners
Parties
Target
XRXOMA Royalty Corporation
- Headquarters
- United States
- Ticker
- XOMA
Acquirer
LPLigand Pharmaceuticals Incorporated
- Headquarters
- United States
- Ticker
- —